null

null

null

null

-489.84x Total Debt / Equity (Negative equity)

Low direct sensitivity; pre-revenue biotech with minimal debt, primarily equity-financed, though rising rates increase cost of future capital raises

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API synthesis suppliers (likely China-based chemical manufacturers) and specialized GMP contract manufacturing organizations (CMOs) represent key chokepoints

Essentially pre-revenue; no meaningful international commercial revenue, so sovereign currency devaluation exposure is negligible at this stage

Operations concentrated in Huntsville, Alabama, USA; no material international revenue exposure; currency devaluation risk effectively zero currently

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or few CMOs for POZ-based polymer synthesis; substitution would require lengthy re-validation, representing non-substitutable operational risk

Cloud disruption risk is low-to-moderate; research data and informatics could be disrupted but core drug development IP is not cloud-dependent

Preclinical/clinical-stage biopharma; secondary model involves potential licensing or partnership deals leveraging POZ platform technology

Moderate API coupling risk; proprietary POZ chemistry platform creates internal lock-in but external software API dependencies are likely minimal

Low Howey Test risk; equity shares in a traditional C-corp drug development company, not a tokenized or investment-contract structure

Very High

Low current GDPR/CCPA exposure; clinical trial patient data will create compliance obligations as trials expand internationally, requiring proactive data governance

Minimal antitrust risk; small-cap early-stage biotech with no market dominance, no pricing power in established markets, no horizontal consolidation concerns

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently ~0% recurring commercial revenue; revenue entirely grant-based (NIH, DoD) and potential milestone payments; no commercial product launched

Primary monetization via future drug sales and/or platform licensing/partnerships; currently sustained by non-dilutive grants and equity financing

No commercial pricing established; future pricing will follow specialty pharma models, likely outcomes-based or payer-negotiated for CNS/pain indications

Potential high pricing power if POZ-based drugs demonstrate superior safety/efficacy vs. opioids; unproven until Phase 2/3 data available; rated speculative

78.5% Gross Margin (Premium (>60%))

No free-rider risk applicable; pre-commercial biotech with grant funding and no subscription or platform-access revenue model

Growth is headcount-sublinear near-term; platform leverage means CROs/CMOs absorb scale costs; internal headcount grows modestly relative to pipeline expansion

Marginal cost of pipeline expansion dominated by CRO/CMO outsourcing and trial costs, not internal headcount; favorable operational leverage at commercial scale

Not applicable; Serina is not a franchise business model

At 10x scale (commercial launch), CAC equivalent is physician/payer adoption cost; specialty pharma sales force economics typically require $500M+ revenue for profitability

No meaningful network effects; drug development is not a network-effect business; value is IP and clinical data moat, not user-base compounding

-276.2% Return on Assets (Negative equity)

Moderate recession resistance as a development-stage company; grant funding provides near-term buffer, but equity capital access tightens significantly in downturns

Primary future customer: patients with chronic pain/CNS disorders and their prescribing physicians; currently dependent on NIH/DoD as grant customers

Secondary customers: pharmaceutical partners or licensees for POZ platform; high concentration risk given small number of potential strategic acquirers/partners

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

45.4% CapEx / Revenue (High-CapEx Infrastructure)

0001708599

SER